Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Mary T Szela is CEO AND PRESIDENT at Trisalus Life Sciences. OQRO lists 14 transactions filed with the SEC under this name, the latest on Oct 7, 2026, each linked to the official Form 4.
CEO AND PRESIDENT
Disclosures on record
14
Companies involved
1
4 buys, median +5.3 pts vs S&P 500, beat it 3 of 4 times.
Average +6.0 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Jan 29, 2025 to May 18, 2026, measured from the first close after the filing. Past results, not a forecast.
4 purchases disclosed; 75% of the 4 measured at 90 days finished ahead of the index. $1,000 placed after each of the 2 purchases disclosed since 2025-11-16 would be worth $1.2K today ($2K put in); the same in the S&P 500 (SPY): $2.1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Trisalus Life SciencesTLSI
14 disclosures · Jan 2025 – Oct 2026 · 6 bought · 2 sold
Oct 5, 20262,693disclosed Oct 7
DetailsOfficial recordJun 30, 20263,990disclosed Jul 1
DetailsEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
May 15, 2026Bought~$103Kdisclosed May 18
DetailsOfficial recordMar 17, 2026Sold~$61Kdisclosed Mar 20
DetailsOfficial recordMar 11, 2026Sold~$18Kdisclosed Mar 20
DetailsOfficial recordFeb 23, 2026Bought~$125K
DetailsOfficial recordNov 24, 2025125Kdisclosed Nov 25
DetailsOfficial recordFeb 13, 2024125Kdisclosed Nov 25
DetailsOfficial recordNov 24, 2025300Kdisclosed Nov 25
DetailsOfficial recordNov 24, 2025250Kdisclosed Nov 25
DetailsOfficial recordJan 30, 2025Bought~$26Kdisclosed Jan 31
DetailsOfficial recordJan 29, 2025Bought~$25Kdisclosed Jan 31
DetailsOfficial recordJan 27, 2025Bought~$26Kdisclosed Jan 29
DetailsOfficial recordJan 28, 2025Bought~$24Kdisclosed Jan 29
DetailsOfficial recordAs of the latest filing on , Mary T Szela reported holding 1,074,990 shares of Trisalus Life Sciences (TLSI), worth about $2.44M at the last close of $2 (Nov 16, 2026). In the last 12 months, Mary T Szela bought $228K in 2 open-market purchases and sold $79K in 2 sales.
Trisalus Life Sciences's proxy statement reports total compensation of $4.82M for Mary T Szela for fiscal year 2025. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Mar 31, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Trisalus Life Sciences TLSI | 1,074,990 | 1.07M direct | $2 | $2.44M | Oct 5, 2026 |
Is this Mary T Szela’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Mary T Szela bought shares on the open market in 2024, 2025 and 2026 across 3 companies. Sales in 7 of the 20 years since 2007.
Mary T Szela reported 10 open-market purchases and 64 sales since 2007; purchases in 3 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $228K2×2 trades | $79K2×2 trades |
| 2025 | $102K4×4 trades | — |
| 2024 | $100K4×4 trades | — |
| 2020 | — | $967K1×1 trade |
| 2011 | — | $4.49M34×34 trades |
| 2010 | — | $1.36M17×17 trades |
| 2009 | — | $477K3×3 trades |
| 2008 | — | $187K6×6 trades |
| 2007 | — | $437K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Oct 5, 2026, Mary T Szela reported holding 1,074,990 shares of Trisalus Life Sciences (TLSI). At the last close of $2 on Nov 16, 2026, that is about $2.44M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Mary T Szela reported 2 open-market sales worth $79K and 2 open-market purchases worth $228K. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Trisalus Life Sciences's proxy statement reports total compensation of $4.82M for Mary T Szela for fiscal year 2025. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Mary T Szela bought shares on the open market in 2024, 2025 and 2026 across 3 companies. Sales in 7 of the 20 years since 2007.
In SEC filings since 2007: the latest open-market purchase is from 2026; the latest open-market sale is from 2026.
3 companies: Trisalus Life Sciences (TLSI, 2024–2026), Coherus Oncology (CHRS, 2020), Abbott Laboratories (ABT, 2007–2011).
Mary T Szela reported 0 open-market purchases and 61 sales here, 2007 to 2011.
Mary T Szela reported 10 open-market purchases and 2 sales here, 2024 to 2026.
Mary T Szela reported 0 open-market purchases and 1 sale here, 2020.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.